BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24184416)

  • 1. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 3. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 5. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
    Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
    Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
    [No Abstract]   [Full Text] [Related]  

  • 6. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
    Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
    [No Abstract]   [Full Text] [Related]  

  • 7. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
    Yiu ZZ; Ali FR; Griffiths CE
    Clin Exp Dermatol; 2016 Jun; 41(4):407-9. PubMed ID: 26667599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
    Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
    Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
    [No Abstract]   [Full Text] [Related]  

  • 9. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
    Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
    J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
    Huang YH; Siao FY; Yen HH
    Gastroenterology; 2015 Aug; 149(2):e12-3. PubMed ID: 26123559
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 12. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
    Tajiri K; Nakajima T; Kawai K; Minemura M; Sugiyama T
    Intern Med; 2015; 54(6):597-600. PubMed ID: 25786448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 14. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
    Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
    Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 16. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 17. Painful Rashes on the Palms and Soles.
    Bhullar M; Bhullar A; Arachchi NJ
    Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
    Hung CT; Chiang CP; Wu BY
    J Dermatol; 2012 Dec; 39(12):1076-7. PubMed ID: 22724918
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
    Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
    [No Abstract]   [Full Text] [Related]  

  • 20. Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
    Grieco A; Lombardo A; Biolato M
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):1001-2. PubMed ID: 23817448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.